A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

NCT01717898 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Dose limiting toxicities on lowest dose level

Conditions

Castrate-resistant Prostate Cancer

Interventions

DRUG: BEZ235
DRUG: Prednisone
DRUG: Abiraterone acetate

Sponsor

Charles Ryan

Collaborators

[object Object]